LYSERGIC ACID DIETHYLAMIDE (LSD-25)
Abstract
Lysergic acid diethylamide (LSD-25 Sandoz) given orally in single doses as low as 20 micrograms produces depersonalization, derealization, and increased imagery in "normal" individuals. Larger doses are required to produce the same effect in psychotic patients.
Of 15 patients with depressive reactions, 3 recovered and 4 improved after one month's treatment with daily oral doses of 20-100 micrograms of LSD. Four patients showed no improvement. In 4 cases, treatment was discontinued before proper evaluation could be made. Anxiety was a prominent reaction while less frequently euphoria was observed. In 3 patients who developed euphoria it served as an aid to psychotherapy by encouraging expression of feeling. In the others the heightened anxiety encouraged reticence rather than confidence.
Improvement obtained during the course of LSD therapy was not greater than that obtained without its use in comparable cases. However, LSD affords therapeutically valuable insights into unconscious processes by the medium of the hallucinations it produces.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
